| Document |
Document Title |
|
WO/2024/090489A1 |
The present invention pertains to a method for producing a radioactive pharmaceutical composition which is a liquid and which comprises, as an active ingredient, a radioactive-labeled antibody, which is an antibody labeled with a radionu...
|
|
WO/2024/086891A1 |
The present invention relates generally to the identification and/or treatment of cancer and in particular cancers in which gastrin releasing peptide receptor (GRPR) is expressed. In particular embodiments, the present invention relates ...
|
|
WO/2024/088879A1 |
The present invention relates to a nanoparticle comprising a block copolymer comprising or consisting of a hydrophobic block and a hydrophilic block. The present invention further relates to a pharmaceutical composition comprising a nano...
|
|
WO/2024/090571A1 |
Provided are: a method for detecting immune-mediated inflammatory diseases characterized by an increase in the expression of MMP12 in a subject; a diagnostic drug containing a substance that specifically interacts with MMP12; and a thera...
|
|
WO/2024/090488A1 |
The present invention pertains to a liquid pharmaceutical composition that contains, as an active ingredient, a complex of a radioactive isotope and an antibody. The pharmaceutical composition is characterized in that: the antibody speci...
|
|
WO/2024/088798A1 |
The present invention relates to microcapsules comprising a hydrophobic core within a polymeric shell, wherein a) the polymeric shell is formed from shell components comprising: i) a polyisocyanate, wherein the polyisocyanate is selected...
|
|
WO/2024/086828A2 |
Compositions, devices, and methods of using one or more hydrogel for contraception are disclosed. In embodiments, the compositions and devices comprise one or more contrast agent, rendering the compositions and devices radiopaque. Includ...
|
|
WO/2024/083224A1 |
The present invention discloses compounds of Formula (I) and their complexes with radionuclides that can recognize both Somatostatin type 2 receptor (SSTR2) and cholecystokinin 2 receptor (CCK2R) and can be used in the diagnosis and trea...
|
|
WO/2023/154564A3 |
CD206 targeted peptide conjugates are provided. Aspects of the conjugates include a CD206 binding peptide conjugated to a label or therapeutic agent. Also provided are methods of using the conjugates, e.g., in diagnostic or therapeutic a...
|
|
WO/2024/079330A1 |
The present invention relates to the provision of a device and a method which allow rapid, safe and reproducible generation of a radiolabeled dry aerosol. The dry aerosol according to the invention allows reproducible imaging of the alve...
|
|
WO/2024/074145A1 |
A bispecific antibody, which comprises: (a) a first antigen-binding portion that specifically binds to a first antigen, the first antigen being BAFFR; (b) a second antigen-binding portion that specifically binds to a second antigen, the ...
|
|
WO/2024/074548A1 |
The current invention relates to an immunoglobulin single variable domain that is directed against and/or that specifically binds to human urokinase plasminogen activator receptor (human uPAR, SEQ ID NO: 1), wherein the immunoglobulin si...
|
|
WO/2024/077006A1 |
Described herein are radiotherapeutics that target tumor cells expressing the follicle-stimulating hormone receptor (FSHR) and their use in the treatment and/or diagnosis of cancer.
|
|
WO/2024/073549A1 |
Disclosed are compositions and methods for the imaging of bacterial infection and differentiation of bacterial infection with inflammation and presence of bacterial in the host body. One embodiment of the composition comprises a radiopha...
|
|
WO/2024/069592A1 |
The present application discloses specific compounds of Formula (I) and their use in therapy, in particular, their use as Polymerase Theta (Polθ) inhibitors for the treatment of cancer. The application further discloses the use of a com...
|
|
WO/2024/066540A1 |
The present application relates to an aspartic acid protease targeted recognition PET molecular probe and use, which pertain to the technical field of chemistry. The present application provides a molecular probe. In the molecular probe,...
|
|
WO/2024/061483A1 |
The present invention relates to a tetrapeptide binding to Cholecystokinin 2 receptor (CCK-2R), wherein the tetrapeptide is represented by formula (I) Xaa1-Xaa2-Xaa3-Xaa4 (formula (I)) or salt thereof, wherein Xaa1 is Trp, (β-(3-benzoth...
|
|
WO/2024/063095A1 |
The prevent invention provides a radiolabeled tyrosine derivative which has excellent LAT1 selectability, higher retention at a tumor or cancer site, and a degree of clearance that does not cause side effects, and which can be safely man...
|
|
WO/2024/059908A1 |
Processes for the synthesis of [89Zr]ZrCl4 from [89Zr][Zr(oxalate)4]4- salt are provided. The [89Zr]ZrCl4 can be reacted with biomarker targeting agents to produce 89Zr labelled radiopharmaceuticals. The 89Zr labelled radiopharmaceutical...
|
|
WO/2024/064968A1 |
The present disclosure relates to the field of fibroblast activation protein (FAP) inhibitors, conjugates comprising the novel FAP inhibitors, including radiotracers, for the imaging, diagnosis and treatment of conditions characterized b...
|
|
WO/2024/064969A2 |
The present disclosure relates to the field of nuclear imaging and therapy, and more specifically to high purity copper radiotracer compositions useful in imaging, such as positron emission tomography (PET) and single-photon emission com...
|
|
WO/2024/055075A1 |
The present invention relates to radiolabelled molecules, and related precursor molecules, for use in detecting immune cells expressing a receptor comprising an antigen binding site for binding to dysfunctional P2X7 receptor and a signal...
|
|
WO/2024/058201A1 |
The purpose of the present invention is to produce an intermediate for a radioactive antibody drug having a higher purity. A production method of the present invention includes an adsorption step for adsorbing a composition containing an...
|
|
WO/2024/057277A1 |
The present disclosure relates to a compound or pharmaceutically acceptable salt thereof comprising at least one bisphosphonate or bisphosphonate ester group, and a positron emitting radionuclide Po, and the use thereof in a method of di...
|
|
WO/2024/056805A1 |
The present invention relates to new and inventive compounds of formula (I). The compounds are useful as PET (positron emission tomography) tracer.
|
|
WO/2024/059650A2 |
Theranostic agents for targeting Gastrin Releasing Peptide Receptor (GRPR) and Prostate Specific Membrane Antigen (PSMA) expressing cells, and use of these agents for detection, staging, and therapy of primary and metastatic prostate can...
|
|
WO/2024/055003A1 |
The present disclosure relates generally to antibodies reactive with drug-peptide conjugates, as well as drug-peptide-binding fragments thereof. The present disclosure also relates to nucleic acids, expression cassettes, and expression v...
|
|
WO/2024/054972A2 |
The present invention provides a compound having the structure: or salt or ester thereof.
|
|
WO/2024/052886A1 |
A sheet for radiotherapy, which includes a sheet base configured for placement on tissue of a patient and a radium-binding material coupled to the base sheet. Alpha-emitting radium radionuclides are coupled to the radium-binding material...
|
|
WO/2024/052549A1 |
The present invention relates to a new class of compounds of general formula (I), to the metal chelates with a metal ion suitable for computed tomography thereof, to the Gd3+ chelate complexes thereof, to methods of preparing said compou...
|
|
WO/2024/050440A2 |
PSMA targeted metal chelate nanodrugs, methods of making these nanodrugs and methods of using them for radiodiagnosis and radiotherapy are provided.
|
|
WO/2024/047112A1 |
The present invention relates to halogenated somatostatin analogs with selectivity for multiple somatostatin receptor subtypes and pharmaceutical compositions comprising the same. Moreover, the present invention relates to said halogenat...
|
|
WO/2024/049281A1 |
The present invention relates to a composition for delivering a diagnostic or therapeutic substance for cancer, comprising a radioactive material. The present invention is a result of research for developing effective and accurate diagno...
|
|
WO/2024/046468A1 |
The present disclosure relates to fusion proteins for degradation of target proteins through lysosomal degradation pathway, and cells comprising such fusion proteins (e.g., chimeric antigen receptor (CAR) -expressing cells). The present ...
|
|
WO/2024/046469A1 |
Provided is a cyclic peptide, which has a sequence of cyclo(X1X2X3X4X5X6), wherein X1 is asparagine; X2 is glycine or sarcosine; X3 is arginine; X4 is selected from a group consisting of threonine, tyrosine, and phenylalanine; X5 is lysi...
|
|
WO/2024/044621A1 |
Various aspects described herein relate to a functionalized nanoscale substrate. The functionalized nanoscale substrate includes a functionalized surface of the substrate that includes a boronated portion.
|
|
WO/2024/044552A1 |
Described herein are immunoconjugates comprising an: a) antigen binding region; b) an immunoglobulin heavy chain constant region; and c) a radioisotope chelating agent; wherein the molecular weight of said immunoconjugate is between 60 a...
|
|
WO/2024/044551A1 |
Described herein are immunoconjugates comprising a multivalent antibody and a chelating agent, wherein the multivalent antibody comprises a polypeptide comprising: a first antigen-binding domain; and a second antigen-binding domain.
|
|
WO/2024/044276A1 |
Ballistic microscopy - a completely new approach to " image" a cell utili zing particle bombardment, is described. These are ballistic micro and nano particles that travel through a cell at ballistic speed and capture a pico or femto-lit...
|
|
WO/2024/044765A2 |
Provided are fibroblast activation protein alpha (FAPα)-cleavable pro-peptides that find use in treating conditions associated with FAPα expression. The FAPα-cleavable pro-peptides also find use in imaging locations of FAPα activity ...
|
|
WO/2024/044549A1 |
Described herein are immunoconjugates comprising an: a) antigen binding region; b) an immunoglobulin heavy chain constant region; and c) a radioisotope chelating agent; wherein the molecular weight of said immunoconjugate is between 60 a...
|
|
WO/2024/044550A1 |
Described herein are heavy chain antibodies that bind to DLL3 and immunoconjugates of DLL3 heavy chain antibodies useful for cancer therapy.
|
|
WO/2024/044554A1 |
Described herein are immunoconjugates comprising an: a) antigen binding region; b) an immunoglobulin heavy chain constant region; and c) a radioisotope chelating agent; wherein the molecular weight of said immunoconjugate is between 60 a...
|
|
WO/2024/044746A2 |
The present disclosure is directed to liposomes and their use in delivery and release of drugs upon exposure to ionizing radiation. More particularly, the liposomes of the present invention comprise a cation triggered membrane permeabili...
|
|
WO/2024/044755A2 |
Compounds comprising a targeting moiety that specifically binds to HSP90, in particular, extracellular HSP90. Also disclosed are pharmaceutical compositions and methods of treating cancer with the same.
|
|
WO/2024/036372A1 |
The present invention relates to formulations of radiolabelled compounds that are of use in radiotherapy and diagnostic imaging. Specifically, the present invention relates to aqueous formulations of 67 Cu radiolabelled compounds of Form...
|
|
WO/2024/040220A2 |
The disclosure provides a fusion protein comprising a CD83 binding domain comprising the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 23, and SEQ ID NO: 24 and an Fc domain, as well as methods of use.
|
|
WO/2024/039743A1 |
This disclosure relates to compositions and methods for selective labeling of compounds containing primary amides. In certain embodiments, the primary amide is present in peptides containing the amino acids asparagine and/or glutamine. I...
|
|
WO/2024/031155A1 |
This application relates generally to prostate specific membrane antigen (PSMA) targeting radiopharmaceutical compounds, and their uses in nuclear medicine for the in- vivo imaging of various tissues, and the treatment and/or prevention ...
|
|
WO/2024/034759A1 |
The present invention relates to: an imaging agent of a PET-based imaging method, the agent comprising 89Zr-labeled anti-CD25 antibodies; and a tumor imaging method or tumor-infiltrating regulatory T cell imaging method using same. The u...
|
